Repare Therapeutics Inc. Stock Price, News & Analysis

Repare Therapeutics Inc. (Nasdaq: RPTX) announced its participation in two investor conferences: the Guggenheim Oncology Conference on February 9, 2023, at 3:20 p.m. ET in New York, and the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:50 a.m. ET in Boston. Investors can access live webcasts of the events via the Company’s website, with replays available for 30 days. Repare is focused on precision oncology, using its proprietary SNIPRx® platform for developing targeted cancer therapies, including ongoing Phase 1 trials of RP-6306 and camonsertib (RP-3500), and additional preclinical programs.

Repare Therapeutics Inc. (NASDAQ: RPTX) announced a $1.5 million research service payment from Ono Pharmaceutical Co., Ltd. This payment is part of their 2019 Strategic Partnership Agreement, linked to the Polθ program (RP-2119). The funding indicates a key milestone as Repare progresses towards IND-enabling studies and prepares for clinical trials anticipated to start in summer 2023. To date, the Ono Agreement has facilitated approximately $8.1 million in funding for Repare, evidencing ongoing collaboration and financial support for its oncology research initiatives.

Repare Therapeutics Inc. (RPTX) announced the establishment of Automatic Securities Disposition Plans (ASDPs) for its executives, allowing them to sell up to 422,512 common shares over approximately 15 months. This move complies with U.S. and Canadian regulations, ensuring trades occur only when the executives do not possess any material non-public information. The ASDPs provide structured selling parameters while limiting amendments to prevent insider trading advantages. The company is focused on precision oncology, utilizing its SNIPRx® platform to develop therapies for genomic instability.

Repare Therapeutics reported Q3 2022 financial results, achieving a net income of $75.5 million, or $1.71 per diluted share, compared to a net loss of $30.9 million the previous year. The company holds $370.4 million in cash, sufficient to fund operations into 2026. Key developments include advancing RP-6306 in Phase 1 trials, with early data expected in H1 2023, and a collaboration with Roche for camonsertib, which includes a $125 million upfront payment and potential total milestone payments up to $1.172 billion.

Repare Therapeutics Inc. (NASDAQ: RPTX) has announced participation at two upcoming investor conferences in November 2022. The first is the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14 at 10:00 a.m. ET. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:00 p.m. ET, taking place in New York, NY. Investors can access live webcasts of both events on the Company’s website, with replays available for 90 days. Repare focuses on precision oncology and utilizes its proprietary SNIPRx® platform for novel cancer therapies.

Repare Therapeutics Inc. (NASDAQ: RPTX) will participate in two investor conferences in September 2022. The first event is the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 2:55 p.m. ET in New York. The second is the Guggenheim Nantucket Therapeutics Conference on September 28 at 8:00 a.m. ET in Nantucket, MA. Live webcasts will be available on the company’s website, and replays will be accessible for 90 days. Repare focuses on precision oncology, utilizing its SNIPRx® platform to develop targeted cancer therapies.

Repare Therapeutics has signed a worldwide license and collaboration agreement with Roche for camonsertib (RP-3500) aimed at advanced solid tumors. Repare received a $125 million upfront payment and could earn up to $1.172 billion in milestones, plus royalties on global sales. The company expects clinical data for RP-6306 in early 2023, having initiated IND-enabling studies for RP-2119. Financial results show a net loss of $38.1 million for Q2 2022, up from $26.3 million in Q2 2021, despite increased R&D investments aimed at advancing its oncology pipeline.

Repare Therapeutics Inc. (Nasdaq: RPTX), a clinical-stage precision oncology company, announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 03:20 p.m. PT. The event will take place in Rancho Palos Verdes, CA. A live webcast will be available on the Company’s website, with an archived replay for 90 days. Repare specializes in cancer therapies using its SNIPRx® platform, focusing on genomic instability and DNA damage repair, and is currently developed leading products like camonsertib (RP-3500) and RP-6306.

Repare Therapeutics has entered a worldwide license and collaboration agreement with Roche for the development of camonsertib (RP-3500), a selective ATR inhibitor targeting specific tumors. Repare will receive a $125 million upfront and could earn up to $1.2 billion in potential milestones and royalties. Roche will lead development, utilizing its expertise to expand treatment options. A conference call will be held today at 5:00 p.m. EDT to discuss this collaboration.